Replies to post #21527 on BioCurex, Inc.(fka BOCX)

[Kag]

Rich, in other words, what you are saying is that selling RECAF is going to require a huge sales effort and I agree. Setting up a website and expecting the sales to come to you is a bit preposterous. The one detail (that you haven't mentioned) that goes along with a huge sales effort is money. Lots of money, which by the way, BioCurex doesn't have. As an investor, I would factor in the possibility, in this economic recession, that Inverness may have delayed work on RECAF. So where does that possbility leave BioCurex? Like right now attempting to increase the number of authorized shares another 175 million. Which brings up one fairly common problem with investing in a biotech too early. You never know the magnitude of the dilution that may occur after you have all the stock you think you need. kag